Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome

项目摘要/摘要 外伤性急性呼吸功能障碍综合征(ARDS)是一种致命的情况，在这种情况下，肺功能衰竭 由身体另一部位的创伤性损伤造成的。最近，几项研究建立了一种联系 循环中的组蛋白和肺衰竭之间的关系。创伤会导致大量细胞死亡， 导致高浓度的组蛋白释放到循环中，这可能直接导致ARDS，AS 组蛋白会损害肺部。此外，循环中的组蛋白加剧了夸张的支持和反对 炎症反应，也会对肺部和其他器官造成损害。身份识别和 创伤触发的循环组蛋白的量化将提供一种评估ARDS风险的方法， 这可以在患者出现ARDS之前进行挽救生命的治疗。及早提供诊断解决方案 创伤后组蛋白的检测应该是便携和快速的，以便在不久之后对患者进行评估 伤害就会发生。然而，目前还没有便携和快速的方法来检测 循环组蛋白用于评估创伤患者发生ARDS的风险。我们的目标是开发一种诊断方法 能够在护理点定量评估创伤引起的ARDS风险的工具。今年5月 包括在受伤地点，在前往创伤中心的运输车辆中，在急诊科(ED)中，或 在手术室(OR)。我们已经发明了一种便携式组蛋白分析技术(PHAST)，它可以 在30分钟内直接从全血中定量循环组蛋白。 。

PROJECT SUMMARY/ABSTRACT Trauma-induced acute respiratory dysfunction syndrome (ARDS) is a deadly condition in which lung failure results from a traumatic injury to another part of the body. Recently, several studies have established a link between circulating histones and lung failure. Traumatic injuries cause a massive amount of cell death, resulting in the release of high concentrations of histones into circulation, which can directly lead to ARDS, as histones damage the lungs. In addition, circulating histones exacerbate exaggerated pro- and anti- inflammatory responses that also result in damage to the lungs and other organs. Identification and quantification of trauma-triggered circulating histones would provide an approach to assess the risk of ARDS, which could enable life-saving therapies before a patient develops ARDS. Diagnostic solutions to provide early detection of histones following trauma should be portable and rapid in order to assess the patient soon after the injury occurs. Currently, however, there are no portable and rapid approaches that enable detection of circulating histones to assess a trauma patient’s risk of developing ARDS. Our goal is to develop a diagnostic tool that is capable of quantitatively assessing the risk of trauma-induced ARDS at the point of care. This may include at the point of injury, in the transport vehicle to a trauma center, in the Emergency Department (ED), or in the operating room (OR). We have invented a Portable Histone Assay Technology (PHAST) that can quantify circulating histones directly from whole blood within 30 minutes. .